In response to the Prime Minister’s speech today regarding leaving the EU, Aisling Burnand CEO of the Association of Medical Research Charities (AMRC) said:
“Uncertainty about the future has not only been a major concern to those involved in developing new drugs and treatments but also to those who benefit from it the most – patients. Although the PM’s clarification today around plans for the UK’s future relationship with the EU focused largely on trade, we must not ignore the implications for access to new and innovative medicines and other technologies.
“The UK currently operates within strong regulatory frameworks across the EU which are vital for medical research particularly clinical trials and, once developed, patient access to these treatments. These frameworks help minimise delays in accessibility for those patients who need new therapies.
“Science and research rightfully feature in the 12 objectives for negotiations outlined during the speech. We welcome the Prime Minister’s recognition of the UK’s status as a world leader in science and innovation and the acknowledgement of the importance of collaboration with EU partners in maintaining this.
For further information please contact Carol Bewick, email@example.com, 0207 685 2624.
NOTES TO EDITORS
1.The Association of Medical Research Charities (AMRC) is the national membership organisation for the health and medical research charity world, influencing the policy and research environments by harnessing the collective strengths of our members, to demonstrate the sector’s positive impact on health and wellbeing.
2.AMRC has 138 members which include the largest health and medical charities in the UK: the British Heart Foundation, Cancer Research UK, and the Wellcome Trust. All members, large and small, work to the same high standards ensuring that every pound they spend on research is invested in lifesaving research of the very highest quality.
3.In 2015, health and medical research charities: Invested £1.4bn in research here in the UK
Financed capital projects worth £129m
Funded the salaries of at least 15,000 researchers.